- 2018August 11
Gmax Announces Approval of GMA102 for Investigational New Drug (IND) in China
GMA102 has been approved by Center for Drug Evaluation (CDE, CFDA) for the IND of type 2 diabetes (T2D).
- 2014December 28
Gmax Biopharm closes the A round financing
December 28,2014, Gmax Biopharm closes the A round financing with 43 million RMB. The raised capital is mainly for moving forward the pipeline products to clinical trials.
- 2015October 29
CDE accepted GMA204 IND registration and started on-site inspection
October 29, 2015, the IND registration of GMA204 was accepted by CDE, and an on-site inspection is about to start.
- 2016April 30
GMA102 started phase 1 clinical trial in Australia
April 2016, GMA102 got IND approval from TGA (Australia, Therapeutic Goods Administration) to start the phase 1 clinical trial in Australia.
- 2016September 30
GMA102 IND registration accepted by CDE
September 30, 2016, CDE has accepted the IND registration of GMA 102.